After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Earlier, Yahoo Finance discussed this stock as it revealed Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Fate Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $4.53 and fluctuated between $4.6250 as its day high and $4.1000 as its day low. The current market capitalization of Fate Therapeutics Inc is $446.66M. A total of 2.8 million shares were traded on the day, compared to an average of 1.96M shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, FATE has seen 0 BUY and 1 SELL insider trades, representing the acquisition of 0 and the disposition of 24,363 shares. Over the last 12 months, there were 3 BUYs and 8 SELLs from insiders. Insiders purchased 443,844 shares during that period but sold 44,741.
In the most recent transaction, Wolchko J Scott sold 14,391 shares of FATE for 4.37 per share on Jan 09. After the transaction, the President and CEO now owns 371,248 company shares. In a previous transaction on Jan 09, Valamehr Bahram sold 11,271 shares at 4.38 per share. FATE shares that Chief R&D Officer owns now total 158,069.
Among the insiders who sold shares, TAHL CINDY disposed of 10,874 shares on Jan 09 at a per-share price of $4.37. This resulted in the General Counsel and Secretary holding 142,361 shares of FATE after the transaction. In another insider transaction, Dulac Edward J III sold 7,028 shares at $4.37 per share on Jan 09. Company shares held by the Chief Financial Officer now total 105,775.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for FATE in the last 3 months, the mean price target is $6.32 with high estimates of $13.00 and low estimates of $2.00. In terms of 52-week highs and lows, FATE has a high of $7.08 and a low of $1.63.
As of this writing, FATE has an earnings estimate of -$0.52 per share for the current quarter. EPS was calculated based on a consensus of 21 estimates, with a high estimate of -$0.32 per share and a lower estimate of -$0.71. The company reported an EPS of -$0.54 in the last quarter, which was 8.50% higher than expectations of -$0.59.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. FATE’s latest balance sheet shows that the firm has $615.91M in Cash & Short Term Investments as of fiscal 2021. There were $114.82M in debt and $81.28M in liabilities at the time. Its Book Value Per Share was $4.09, while its Total Shareholder’s Equity was $678.84M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FATE is Buy with a score of 3.43.
